For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260126:nRSZ3666Qa&default-theme=true
RNS Number : 3666Q Reckitt Benckiser Group PLC 26 January 2026
26 January 2026
Response to inaccurate media article
(London, UK, 26 January 2026)
Reckitt Benckiser Group plc ("Reckitt") confirms that it has not been subject
to a product recall in the Philippines as incorrectly published in a media
article. The Mead Johnson Nutrition product mentioned in the article "Enfamil
ProSobee Simply Plant-Based Infant Formula" is not registered and marketed in
the Philippines.
Investors and Analysts:
Nick
Ashworth
+44 (0)7408
812350
Jon Bone
+44 (0)7408 811493
Media:
Richard Farnsworth, Corporate Communications
+44 (0)7734 776317
Will Hill, Media Relations
+44 (0)7970 404917
About Reckitt:
We make the products people trust to care for the ones they love. We are home
to some of the world's best-loved consumer health and hygiene brands,
including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen,
Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By
creating innovative, science-backed solutions, we support people every day to
live healthier lives.
Reckitt exists to protect, heal and nurture in the pursuit of a cleaner,
healthier world. This commitment goes beyond the products we make. Through our
actions, we expand access to healthcare, education and economic opportunities.
We support the planet by reducing waste, conserving resources and driving
sustainable innovation.
We believe good health starts at home. With every action we take, we strive to
make our consumers' lives easier, cleaner and healthier, to strengthen
communities and to create a more sustainable future.
*Reckitt is the trading name of the Reckitt group of companies
LEI: 5493003JFSMOJG48V108
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END SPCFZGZMGVNGVZM
Copyright 2019 Regulatory News Service, all rights reserved